Table 1 Patient and sample characteristics.
Variables | PD-L1 immunohistochemistry (22C3 pharmDx) | Total | P value | |||
|---|---|---|---|---|---|---|
Negative (CPS = 0) | Positive (CPS ≥ 1) | |||||
Age | ||||||
<60 | 24 | (80.0%) | 9 | (36.0%) | 33 | 0.001 |
≥60 | 6 | (20.0%) | 16 | (64.0%) | 22 | |
Sex | ||||||
Male | 15 | (50.0%) | 21 | (84.0%) | 36 | 0.008 |
Female | 15 | (50.0%) | 4 | (16.0%) | 19 | |
Differentiation | ||||||
Well differentiated | 1 | (3.3%) | 1 | (4.0%) | 2 | 0.391a |
Moderately differentiated | 4 | (13.3%) | 7 | (28.0%) | 11 | |
Poorly differentiated | 25 | (83.3%) | 17 | (68.0%) | 42 | |
Lauren classification | ||||||
Intestinal | 6 | (20.0%) | 8 | (32.0%) | 14 | 0.414a |
Diffuse | 21 | (70.0%) | 12 | (48.0%) | 33 | |
Mixed | 2 | (6.7%) | 3 | (12.0%) | 5 | |
Indeterminate | 1 | (3.3%) | 2 | (8.0%) | 3 | |
Stage | ||||||
I | 3 | (10.0%) | 1 | (4.0%) | 4 | 0.739a |
II | 3 | (10.0%) | 4 | (16.0%) | 7 | |
III | 17 | (56.7%) | 16 | (64.0%) | 33 | |
IV | 7 | (23.3%) | 4 | (16.0%) | 11 | |
Neoadjuvant chemotherapy | ||||||
Not performed | 30 | (100%) | 21 | (84.0%) | 51 | 0.037a |
Performed | 0 | (0%) | 4 | (16.0%) | 4 | |
Tissue type | ||||||
Stomach resection | 24 | (80.0%) | 25 | (100%) | 49 | 0.076a |
Stomach biopsy | 2 | (6.7%) | 0 | (0%) | 2 | |
Peritoneal biopsy | 4 | (13.3%) | 0 | (0%) | 4 | |
HER2 | ||||||
Negative | 29 | (96.7%) | 25 | (100%) | 54 | 1a |
Positive | 1 | (3.3%) | 0 | (0%) | 1 | |
EBV | ||||||
Negative | 29 | (100%) | 20 | (83.3%) | 49 | 0.036a |
Positive | 0 | (0%) | 4 | (16.7%) | 4 | |
MSI | ||||||
MSS | 20 | (95.2%) | 14 | (77.8%) | 34 | 0.162a |
MSI-high | 1 | (4.8%) | 4 | (22.2%) | 5 | |
Tumor-infiltrating lymphocytes | ||||||
Low | 24 | (80.0%) | 14 | (56.0%) | 38 | 0.055 |
High | 6 | (20.0%) | 11 | (44.0%) | 17 | |
Total | 30 | (54.5%) | 25 | (45.5%) | 55 | |
